Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-20-018493

Options or other derivatives

  • Chief Executive Officer acquired 177,500 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Kulkarni Samarth Chief Executive Officer 2020-03-10 Grant or award · Stock Option (Right to Buy) +142,000 142,000 D
Kulkarni Samarth Chief Executive Officer 2020-03-10 Grant or award · Restricted Stock Units +35,500 35,500 D
Loading xslF345X03/doc4.xml…